Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder
NCT ID: NCT00095524
Last Updated: 2013-11-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
300 participants
INTERVENTIONAL
2004-03-31
2006-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aripiprazole
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Otsuka America Pharmaceutical
INDUSTRY
Otsuka Pharmaceutical Development & Commercialization, Inc.
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution
Little Rock, Arkansas, United States
Local Institution
Anaheim, California, United States
Local Institution
Cerritos, California, United States
Local Institution
Garden Grove, California, United States
Local Institution
National City, California, United States
Local Institution
San Diego, California, United States
Local Institution
New Britain, Connecticut, United States
Local Institution
North Miami, Florida, United States
Local Institution
Augusta, Georgia, United States
Local Institution
Macon, Georgia, United States
Local Institution
Hoffman Estates, Illinois, United States
Local Institution
Louisville, Kentucky, United States
Local Institution
Glen Burnie, Maryland, United States
Local Institution
Haverhill, Massachusetts, United States
Local Institution
Worcester, Massachusetts, United States
Local Institution
Minneapolis, Minnesota, United States
Local Institution
Brooklyn, New York, United States
Local Institution
Nashville, Tennessee, United States
Local Institution
Austin, Texas, United States
Local Institution
Dallas, Texas, United States
Local Institution
DeSoto, Texas, United States
Local Institution
San Antonio, Texas, United States
Local Institution
Wauwatosa, Wisconsin, United States
Local Institution
Goibnia, Goiás, Brazil
Local Institution
Belo Horizonte, Minas Gerais, Brazil
Local Institution
Rio de Janeiro, Rio de Janeiro, Brazil
Local Institution
Porto Alegre, Rio Grande do Sul, Brazil
Local Institution
Botucatu, São Paulo, Brazil
Local Institution
Sao Paulo - Sp, São Paulo, Brazil
Local Institution
São Paulo, São Paulo, Brazil
Local Institution
Exeter, Devon, United Kingdom
Local Institution
Birmingham, West Midlands, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, L'italien GJ, Nys M, Carson WH, McQuade RD. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry. 2008 Jul;69(7):1046-56. doi: 10.4088/jcp.v69n0702.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CN138-122
Identifier Type: -
Identifier Source: org_study_id